FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholder Agreement • May 22nd, 2020 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Contract Type FiledMay 22nd, 2020 Company Industry JurisdictionWHEREAS, the Company, OrbiMed, Casdin, the Key Holders, the WFOE, the HK Company, the Domestic Companies and the other parties thereto are each parties to the Series C+ Preferred Share Purchase Agreement dated as of December 30, 2019 (the “Purchase Agreement”);
FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholder Agreement • January 10th, 2020 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Contract Type FiledJanuary 10th, 2020 Company Industry JurisdictionWHEREAS, the Company, OrbiMed, Casdin, the Key Holders, the WFOE, the HK Company, the Domestic Companies and the other parties thereto are each parties to the Series C+ Preferred Share Purchase Agreement dated as of December 30, 2019 (the “Purchase Agreement”);
FOURTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholder Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Contract Type FiledNovember 4th, 2019 Company Industry JurisdictionWHEREAS, the Company, GIC, the Key Holders, the WFOE, the HK Company, the Domestic Companies and the other parties thereto are each parties to the Series C Preferred Share Purchase Agreement dated as of January 31, 2019 (the “Purchase Agreement”);